Sichuan Kelun Pharmaceutical Co., Ltd. (SHE:002422)

SHE:002422 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	17,595	21,107	20,714	18,601	16,936	16,128
Other Revenue	705.65	705.65	739.64	437.62	341.23	336.6
Revenue	18,300	21,812	21,454	19,038	17,277	16,464
Revenue Growth (YoY)	-18.66%	1.67%	12.69%	10.19%	4.94%	-6.65%
Cost of Revenue	9,558	10,613	10,291	9,084	7,993	7,866
Gross Profit	8,742	11,200	11,163	9,954	9,284	8,598
Selling, General & Admin	4,287	4,801	5,592	5,657	5,877	5,608
Research & Development	2,219	2,171	1,944	1,795	1,737	1,527
Other Operating Expenses	63.78	110.88	184.61	192.45	150.4	198.76
Operating Expenses	6,602	7,156	7,756	7,694	7,800	7,377
Operating Income	2,140	4,044	3,407	2,260	1,484	1,221
Interest Expense	-111.78	-151.62	-361.54	-475.22	-518.34	-554.86
Interest & Investment Income	300.58	416.62	462.47	278.81	244.03	125.2
Currency Exchange Gain (Loss)	16.89	16.89	33.36	-41.86	-2.31	-46.12
Other Non Operating Income (Expenses)	-97.11	-44.08	-18.95	-143.9	-21.84	-31.17
EBT Excluding Unusual Items	2,249	4,282	3,522	1,878	1,186	713.63
Gain (Loss) on Sale of Investments	27.64	19.9	14.67	9.86	4.83	0.42
Gain (Loss) on Sale of Assets	5.67	0.81	2.63	5.4	-7.94	-20.04
Asset Writedown	-102.23	-65.85	-58.62	-1.93	-13.2	-11.24
Other Unusual Items	48.74	48.74	99.62	177	8.38	272.26
Pretax Income	2,229	4,285	3,580	2,068	1,178	955.03
Income Tax Expense	542.91	923.4	933.79	363.7	309.5	163.55
Earnings From Continuing Operations	1,686	3,362	2,647	1,704	868.12	791.48
Minority Interest in Earnings	-20.09	-426.06	-190.53	1.1	234.44	37.91
Net Income	1,666	2,936	2,456	1,705	1,103	829.39
Net Income to Common	1,666	2,936	2,456	1,705	1,103	829.39
Net Income Growth	-43.80%	19.53%	44.03%	54.67%	32.94%	-11.57%
Shares Outstanding (Basic)	1,599	1,578	1,453	1,398	1,414	1,430
Shares Outstanding (Diluted)	1,599	1,578	1,545	1,483	1,414	1,430
Shares Change (YoY)	2.11%	2.18%	4.17%	4.91%	-1.15%	0.06%
EPS (Basic)	1.04	1.86	1.69	1.22	0.78	0.58
EPS (Diluted)	1.04	1.86	1.59	1.15	0.78	0.58
EPS Growth	-44.96%	16.98%	38.26%	47.44%	34.48%	-11.61%
Free Cash Flow	1,346	2,815	3,568	2,230	1,857	988.5
Free Cash Flow Per Share	0.84	1.78	2.31	1.50	1.31	0.69
Dividend Per Share	0.503	0.763	0.800	0.616	0.426	0.319
Dividend Growth	-52.55%	-4.63%	29.87%	44.60%	33.63%	-24.99%
Gross Margin	47.77%	51.35%	52.03%	52.29%	53.74%	52.22%
Operating Margin	11.70%	18.54%	15.88%	11.87%	8.59%	7.41%
Profit Margin	9.10%	13.46%	11.45%	8.96%	6.38%	5.04%
Free Cash Flow Margin	7.35%	12.90%	16.63%	11.71%	10.75%	6.00%
EBITDA	3,356	5,248	4,596	3,416	2,690	2,375
EBITDA Margin	18.34%	24.06%	21.42%	17.94%	15.57%	14.43%
D&A For EBITDA	1,216	1,204	1,189	1,156	1,206	1,155
EBIT	2,140	4,044	3,407	2,260	1,484	1,221
EBIT Margin	11.70%	18.54%	15.88%	11.87%	8.59%	7.41%
Effective Tax Rate	24.36%	21.55%	26.08%	17.59%	26.28%	17.13%
Revenue as Reported	18,300	21,812	21,454	19,038	17,277	16,464
Advertising Expenses	-	145.44	265.58	129.59	161.8	1.78

Source: S&P Global Market Intelligence. Standard template. Financial Sources.